世界の抗血友病因子（組換え）市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Antihemophilic Factor (Recombinant) Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z0393 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、抗血友病因子（組換え）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（250IU、500IU、1000IU、1500IU、2000IU）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・抗血友病因子（組換え）の市場動向 ・企業の競争状況、市場シェア ・抗血友病因子（組換え）の種類別市場規模（250IU、500IU、1000IU、1500IU、2000IU） ・抗血友病因子（組換え）の用途別市場規模（病院、クリニック） ・抗血友病因子（組換え）の北米市場規模2016-2027（アメリカ、カナダ） ・抗血友病因子（組換え）のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・抗血友病因子（組換え）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・抗血友病因子（組換え）の中南米市場規模2016-2027（メキシコ、ブラジル） ・抗血友病因子（組換え）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Takeda、Bayer、CSL、Pfizer、Biogen、Octapharma、NovoNordisk） ・結論

Antihemophilic factor is a naturally occurring protein in the blood that helps blood to clot.

Market Analysis and Insights: Global Antihemophilic Factor (Recombinant) Market
The global Antihemophilic Factor (Recombinant) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antihemophilic Factor (Recombinant) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antihemophilic Factor (Recombinant) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antihemophilic Factor (Recombinant) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antihemophilic Factor (Recombinant) market.

Global Antihemophilic Factor (Recombinant) Scope and Market Size
Antihemophilic Factor (Recombinant) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antihemophilic Factor (Recombinant) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
250IU
500IU
1000IU
1500IU
2000IU

Segment by Application
Hospital
Clinic

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Takeda
Bayer
CSL
Pfizer
Biogen
Octapharma
NovoNordisk

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antihemophilic Factor (Recombinant) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 250IU
1.2.3 500IU
1.2.4 1000IU
1.2.5 1500IU
1.2.6 2000IU
1.3 Market by Application
1.3.1 Global Antihemophilic Factor (Recombinant) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Antihemophilic Factor (Recombinant) Market Perspective (2016-2027)
2.2 Antihemophilic Factor (Recombinant) Growth Trends by Regions
2.2.1 Antihemophilic Factor (Recombinant) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Antihemophilic Factor (Recombinant) Historic Market Share by Regions (2016-2021)
2.2.3 Antihemophilic Factor (Recombinant) Forecasted Market Size by Regions (2022-2027)
2.3 Antihemophilic Factor (Recombinant) Industry Dynamic
2.3.1 Antihemophilic Factor (Recombinant) Market Trends
2.3.2 Antihemophilic Factor (Recombinant) Market Drivers
2.3.3 Antihemophilic Factor (Recombinant) Market Challenges
2.3.4 Antihemophilic Factor (Recombinant) Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Antihemophilic Factor (Recombinant) Players by Revenue
3.1.1 Global Top Antihemophilic Factor (Recombinant) Players by Revenue (2016-2021)
3.1.2 Global Antihemophilic Factor (Recombinant) Revenue Market Share by Players (2016-2021)
3.2 Global Antihemophilic Factor (Recombinant) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Antihemophilic Factor (Recombinant) Revenue
3.4 Global Antihemophilic Factor (Recombinant) Market Concentration Ratio
3.4.1 Global Antihemophilic Factor (Recombinant) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antihemophilic Factor (Recombinant) Revenue in 2020
3.5 Antihemophilic Factor (Recombinant) Key Players Head office and Area Served
3.6 Key Players Antihemophilic Factor (Recombinant) Product Solution and Service
3.7 Date of Enter into Antihemophilic Factor (Recombinant) Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Antihemophilic Factor (Recombinant) Breakdown Data by Type
4.1 Global Antihemophilic Factor (Recombinant) Historic Market Size by Type (2016-2021)
4.2 Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Type (2022-2027)

5 Antihemophilic Factor (Recombinant) Breakdown Data by Application
5.1 Global Antihemophilic Factor (Recombinant) Historic Market Size by Application (2016-2021)
5.2 Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Antihemophilic Factor (Recombinant) Market Size (2016-2027)
6.2 North America Antihemophilic Factor (Recombinant) Market Size by Type
6.2.1 North America Antihemophilic Factor (Recombinant) Market Size by Type (2016-2021)
6.2.2 North America Antihemophilic Factor (Recombinant) Market Size by Type (2022-2027)
6.2.3 North America Antihemophilic Factor (Recombinant) Market Size by Type (2016-2027)
6.3 North America Antihemophilic Factor (Recombinant) Market Size by Application
6.3.1 North America Antihemophilic Factor (Recombinant) Market Size by Application (2016-2021)
6.3.2 North America Antihemophilic Factor (Recombinant) Market Size by Application (2022-2027)
6.3.3 North America Antihemophilic Factor (Recombinant) Market Size by Application (2016-2027)
6.4 North America Antihemophilic Factor (Recombinant) Market Size by Country
6.4.1 North America Antihemophilic Factor (Recombinant) Market Size by Country (2016-2021)
6.4.2 North America Antihemophilic Factor (Recombinant) Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Antihemophilic Factor (Recombinant) Market Size (2016-2027)
7.2 Europe Antihemophilic Factor (Recombinant) Market Size by Type
7.2.1 Europe Antihemophilic Factor (Recombinant) Market Size by Type (2016-2021)
7.2.2 Europe Antihemophilic Factor (Recombinant) Market Size by Type (2022-2027)
7.2.3 Europe Antihemophilic Factor (Recombinant) Market Size by Type (2016-2027)
7.3 Europe Antihemophilic Factor (Recombinant) Market Size by Application
7.3.1 Europe Antihemophilic Factor (Recombinant) Market Size by Application (2016-2021)
7.3.2 Europe Antihemophilic Factor (Recombinant) Market Size by Application (2022-2027)
7.3.3 Europe Antihemophilic Factor (Recombinant) Market Size by Application (2016-2027)
7.4 Europe Antihemophilic Factor (Recombinant) Market Size by Country
7.4.1 Europe Antihemophilic Factor (Recombinant) Market Size by Country (2016-2021)
7.4.2 Europe Antihemophilic Factor (Recombinant) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size (2016-2027)
8.2 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Type
8.2.1 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Type (2016-2027)
8.3 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Application
8.3.1 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Application (2016-2027)
8.4 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region
8.4.1 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Antihemophilic Factor (Recombinant) Market Size (2016-2027)
9.2 Latin America Antihemophilic Factor (Recombinant) Market Size by Type
9.2.1 Latin America Antihemophilic Factor (Recombinant) Market Size by Type (2016-2021)
9.2.2 Latin America Antihemophilic Factor (Recombinant) Market Size by Type (2022-2027)
9.2.3 Latin America Antihemophilic Factor (Recombinant) Market Size by Type (2016-2027)
9.3 Latin America Antihemophilic Factor (Recombinant) Market Size by Application
9.3.1 Latin America Antihemophilic Factor (Recombinant) Market Size by Application (2016-2021)
9.3.2 Latin America Antihemophilic Factor (Recombinant) Market Size by Application (2022-2027)
9.3.3 Latin America Antihemophilic Factor (Recombinant) Market Size by Application (2016-2027)
9.4 Latin America Antihemophilic Factor (Recombinant) Market Size by Country
9.4.1 Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2016-2021)
9.4.2 Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size (2016-2027)
10.2 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Type
10.2.1 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Type (2016-2027)
10.3 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Application
10.3.1 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Application (2016-2027)
10.4 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country
10.4.1 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Details
11.1.2 Takeda Business Overview
11.1.3 Takeda Antihemophilic Factor (Recombinant) Introduction
11.1.4 Takeda Revenue in Antihemophilic Factor (Recombinant) Business (2016-2021)
11.1.5 Takeda Recent Development
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Antihemophilic Factor (Recombinant) Introduction
11.2.4 Bayer Revenue in Antihemophilic Factor (Recombinant) Business (2016-2021)
11.2.5 Bayer Recent Development
11.3 CSL
11.3.1 CSL Company Details
11.3.2 CSL Business Overview
11.3.3 CSL Antihemophilic Factor (Recombinant) Introduction
11.3.4 CSL Revenue in Antihemophilic Factor (Recombinant) Business (2016-2021)
11.3.5 CSL Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Antihemophilic Factor (Recombinant) Introduction
11.4.4 Pfizer Revenue in Antihemophilic Factor (Recombinant) Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 Biogen
11.5.1 Biogen Company Details
11.5.2 Biogen Business Overview
11.5.3 Biogen Antihemophilic Factor (Recombinant) Introduction
11.5.4 Biogen Revenue in Antihemophilic Factor (Recombinant) Business (2016-2021)
11.5.5 Biogen Recent Development
11.6 Octapharma
11.6.1 Octapharma Company Details
11.6.2 Octapharma Business Overview
11.6.3 Octapharma Antihemophilic Factor (Recombinant) Introduction
11.6.4 Octapharma Revenue in Antihemophilic Factor (Recombinant) Business (2016-2021)
11.6.5 Octapharma Recent Development
11.7 NovoNordisk
11.7.1 NovoNordisk Company Details
11.7.2 NovoNordisk Business Overview
11.7.3 NovoNordisk Antihemophilic Factor (Recombinant) Introduction
11.7.4 NovoNordisk Revenue in Antihemophilic Factor (Recombinant) Business (2016-2021)
11.7.5 NovoNordisk Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Antihemophilic Factor (Recombinant) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of 250IU
Table 3. Key Players of 500IU
Table 4. Key Players of 1000IU
Table 5. Key Players of 1500IU
Table 6. Key Players of 2000IU
Table 7. Global Antihemophilic Factor (Recombinant) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Antihemophilic Factor (Recombinant) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Antihemophilic Factor (Recombinant) Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Antihemophilic Factor (Recombinant) Market Share by Regions (2016-2021)
Table 11. Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Antihemophilic Factor (Recombinant) Market Share by Regions (2022-2027)
Table 13. Antihemophilic Factor (Recombinant) Market Trends
Table 14. Antihemophilic Factor (Recombinant) Market Drivers
Table 15. Antihemophilic Factor (Recombinant) Market Challenges
Table 16. Antihemophilic Factor (Recombinant) Market Restraints
Table 17. Global Antihemophilic Factor (Recombinant) Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Antihemophilic Factor (Recombinant) Market Share by Players (2016-2021)
Table 19. Global Top Antihemophilic Factor (Recombinant) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antihemophilic Factor (Recombinant) as of 2020)
Table 20. Ranking of Global Top Antihemophilic Factor (Recombinant) Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Antihemophilic Factor (Recombinant) Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Antihemophilic Factor (Recombinant) Product Solution and Service
Table 24. Date of Enter into Antihemophilic Factor (Recombinant) Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Antihemophilic Factor (Recombinant) Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Type (2016-2021)
Table 28. Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Antihemophilic Factor (Recombinant) Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Application (2016-2021)
Table 32. Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Antihemophilic Factor (Recombinant) Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Antihemophilic Factor (Recombinant) Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Antihemophilic Factor (Recombinant) Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Antihemophilic Factor (Recombinant) Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Antihemophilic Factor (Recombinant) Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Antihemophilic Factor (Recombinant) Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Antihemophilic Factor (Recombinant) Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Antihemophilic Factor (Recombinant) Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Antihemophilic Factor (Recombinant) Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Antihemophilic Factor (Recombinant) Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Antihemophilic Factor (Recombinant) Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Antihemophilic Factor (Recombinant) Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Antihemophilic Factor (Recombinant) Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Antihemophilic Factor (Recombinant) Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Antihemophilic Factor (Recombinant) Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Antihemophilic Factor (Recombinant) Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2022-2027) & (US$ Million)
Table 64. Takeda Company Details
Table 65. Takeda Business Overview
Table 66. Takeda Antihemophilic Factor (Recombinant) Product
Table 67. Takeda Revenue in Antihemophilic Factor (Recombinant) Business (2016-2021) & (US$ Million)
Table 68. Takeda Recent Development
Table 69. Bayer Company Details
Table 70. Bayer Business Overview
Table 71. Bayer Antihemophilic Factor (Recombinant) Product
Table 72. Bayer Revenue in Antihemophilic Factor (Recombinant) Business (2016-2021) & (US$ Million)
Table 73. Bayer Recent Development
Table 74. CSL Company Details
Table 75. CSL Business Overview
Table 76. CSL Antihemophilic Factor (Recombinant) Product
Table 77. CSL Revenue in Antihemophilic Factor (Recombinant) Business (2016-2021) & (US$ Million)
Table 78. CSL Recent Development
Table 79. Pfizer Company Details
Table 80. Pfizer Business Overview
Table 81. Pfizer Antihemophilic Factor (Recombinant) Product
Table 82. Pfizer Revenue in Antihemophilic Factor (Recombinant) Business (2016-2021) & (US$ Million)
Table 83. Pfizer Recent Development
Table 84. Biogen Company Details
Table 85. Biogen Business Overview
Table 86. Biogen Antihemophilic Factor (Recombinant) Product
Table 87. Biogen Revenue in Antihemophilic Factor (Recombinant) Business (2016-2021) & (US$ Million)
Table 88. Biogen Recent Development
Table 89. Octapharma Company Details
Table 90. Octapharma Business Overview
Table 91. Octapharma Antihemophilic Factor (Recombinant) Product
Table 92. Octapharma Revenue in Antihemophilic Factor (Recombinant) Business (2016-2021) & (US$ Million)
Table 93. Octapharma Recent Development
Table 94. NovoNordisk Company Details
Table 95. NovoNordisk Business Overview
Table 96. NovoNordisk Antihemophilic Factor (Recombinant) Product
Table 97. NovoNordisk Revenue in Antihemophilic Factor (Recombinant) Business (2016-2021) & (US$ Million)
Table 98. NovoNordisk Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antihemophilic Factor (Recombinant) Market Share by Type: 2020 VS 2027
Figure 2. 250IU Features
Figure 3. 500IU Features
Figure 4. 1000IU Features
Figure 5. 1500IU Features
Figure 6. 2000IU Features
Figure 7. Global Antihemophilic Factor (Recombinant) Market Share by Application: 2020 VS 2027
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Antihemophilic Factor (Recombinant) Report Years Considered
Figure 11. Global Antihemophilic Factor (Recombinant) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Antihemophilic Factor (Recombinant) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Antihemophilic Factor (Recombinant) Market Share by Regions: 2020 VS 2027
Figure 14. Global Antihemophilic Factor (Recombinant) Market Share by Regions (2022-2027)
Figure 15. Global Antihemophilic Factor (Recombinant) Market Share by Players in 2020
Figure 16. Global Top Antihemophilic Factor (Recombinant) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antihemophilic Factor (Recombinant) as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Antihemophilic Factor (Recombinant) Revenue in 2020
Figure 18. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Type (2016-2021)
Figure 19. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Type (2022-2027)
Figure 20. North America Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Antihemophilic Factor (Recombinant) Market Share by Type (2016-2027)
Figure 22. North America Antihemophilic Factor (Recombinant) Market Share by Application (2016-2027)
Figure 23. North America Antihemophilic Factor (Recombinant) Market Share by Country (2016-2027)
Figure 24. United States Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Antihemophilic Factor (Recombinant) Market Share by Type (2016-2027)
Figure 28. Europe Antihemophilic Factor (Recombinant) Market Share by Application (2016-2027)
Figure 29. Europe Antihemophilic Factor (Recombinant) Market Share by Country (2016-2027)
Figure 30. Germany Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Antihemophilic Factor (Recombinant) Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Antihemophilic Factor (Recombinant) Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Antihemophilic Factor (Recombinant) Market Share by Region (2016-2027)
Figure 40. China Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Antihemophilic Factor (Recombinant) Market Share by Type (2016-2027)
Figure 48. Latin America Antihemophilic Factor (Recombinant) Market Share by Application (2016-2027)
Figure 49. Latin America Antihemophilic Factor (Recombinant) Market Share by Country (2016-2027)
Figure 50. Mexico Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Antihemophilic Factor (Recombinant) Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Antihemophilic Factor (Recombinant) Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Antihemophilic Factor (Recombinant) Market Share by Country (2016-2027)
Figure 56. Turkey Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Antihemophilic Factor (Recombinant) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Takeda Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2016-2021)
Figure 60. Bayer Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2016-2021)
Figure 61. CSL Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2016-2021)
Figure 62. Pfizer Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2016-2021)
Figure 63. Biogen Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2016-2021)
Figure 64. Octapharma Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2016-2021)
Figure 65. NovoNordisk Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2016-2021)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

---